Self-Mixed Morphine Gel Reduces Pain and Systemic Opioid Use in Cancer

Managing localized pain from malignant skin lesions remains a significant clinical hurdle, as systemic opioids frequently fail to provide targeted relief and often induce dose-limiting adverse effects. While clinical guidelines emphasize the importance of multimodal, opioid-sparing strategies to mitigate risks such as respiratory depression and sedation, many patients with advanced disease continue to experience refractory pain [1, 2, 3]. Topical interventions, including morphine mouthwashes and lidocaine patches, have demonstrated efficacy in treating localized mucosal and neuropathic pain by targeting peripheral opioid receptors without the systemic burden [4, 5, 6]. Clinical trials have specifically shown that 0.2% topical morphine can reduce mean pain intensity from a numeric rating scale score of 5.9 to 2.5 (p < 0.0001), with 77% of patients achieving at least 50% pain relief [7]. However, the high cost of professionally compounded topical agents often restricts their use in palliative and hospice settings [3]. A recent study now evaluates a simplified, patient-mixed morphine gel as a practical solution for improving pain control in this vulnerable population.